Study Finds Baricitinib Could Delay Progression of Type 1 Diabetes
A trial comparing baricitinib against placebo in people with new-onset type 1 diabetes suggests use could contribute to the preservation of β-cell function.
Source: ajmc.com
Stay updated with breaking news from Thomas Kay. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A trial comparing baricitinib against placebo in people with new-onset type 1 diabetes suggests use could contribute to the preservation of β-cell function.
Quotable quotes heard by <em>MedPage Today</em>'s reporters
The drug was found to safely preserve the body's insulin production and suppress the advancement of type 1 diabetes when initiated within 100 days of diagnosis.
Type 1 diabetes is a condition with low or no insulin production
A rheumatoid arthritis drug can suppress the progression of type 1 diabetes, a world-first clinical trial has found.